Tiffany & Co. (NYSE: TIF) is scheduled to report second quarter 2019 earnings results on Wednesday, August 28, before the opening bell. The consensus estimate is for earnings of $1.05 per share on revenue of $1.06 billion.
Tiffany has been struggling with declining sales across all its geographical regions. Comparable store sales have also dropped, pulled down by decreases in all its markets. The results have been impacted by lower worldwide spending attributed to foreign tourists, and foreign exchange headwinds. These challenges are likely to continue in the second quarter putting pressure on both the top and bottom line numbers.
There are speculations that the Hong Kong protests could impact tourism and this in turn could take a toll on Tiffany’s sales. The ongoing trade war, the resultant tariffs and the economic headwinds in China might also dampen the topline results.
Tiffany recently launched its men’s jewelry and lifestyle line in order to expand its product offerings and tap into an entirely new customer base. Earlier this month, the company announced its plans to open new stores in India through a joint venture with Reliance Brands Limited. Updates on these efforts will be interesting to watch.
Also see: Tiffany Q1 2019 Earnings Conference Call Transcript
In the first quarter of 2019, Tiffany reported better-than-expected earnings while revenues missed estimates. Net sales fell 3% to $1 billion while EPS dropped 10% to $1.03. Comparable sales decreased 2%. The company saw declines in both net sales and comp sales across all its geographical regions last quarter.
For fiscal 2019, the management expects worldwide net sales to increase by a low-single-digit percentage from last year, reflecting an increase of the same degree in comparable sales. Earnings, on a per share basis, are forecast to grow by a low-to-mid-single-digit percentage.
Tiffany’s shares have gained 7% year-to-date. The stock has an average price target of $103.30.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on